Research Updates

Back to feed
PubMed
Clinical study

High importance

Sep 3, 2026

Safety of antithrombotic therapy in hereditary hemorrhagic telangiectasia: results from a prospective cohort study.

View original source

Why it matters

With limited data on the risk of thrombotic events in HHT patients, findings from this study provide critical insights into the safety of antithrombotic therapy, potentially influencing treatment protocols and improving patient outcomes.

Objective

To evaluate the safety of antithrombotic therapy (AT) in patients with hereditary hemorrhagic telangiectasia (HHT), focusing on bleeding outcomes.

Results

Among 33 patients, 2 major bleeding events (4.9%) occurred during anticoagulant therapy, alongside three clinically relevant nonmajor bleeds and one minor bleed. Worsening of epistaxis was noted in 24.4% of treatment courses, but the mean Epistaxis Severity Score showed no significant baseline change, and hemoglobin levels remained stable with no significant transfusion needs.

Methods

A prospective observational study at a tertiary HHT referral center, enrolling patients with definite HHT requiring antiplatelet or anticoagulant therapy. Incidence of hemorrhagic events was the primary outcome, and secondary outcomes included assessment of epistaxis severity, hemoglobin levels, and transfusion requirements.

Limitations

The study involved a small cohort and was conducted at a single center, limiting generalizability. Larger, multicenter studies are needed to confirm findings.

For your doctor:

PMID: 42834890

DOI: 10.1016/j.rpth.2026.106943

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder characterized by a predominant bleeding phenotype. However, patients are also at risk of thrombotic events and may require antithrombotic therapy (AT), for which safety data remain limited. OBJECTIVES: To prospectively evaluate the safety of AT in patients with HHT using standardized longitudinal assessment of bleeding outcomes. METHODS: We conducted a prospective observational study at a tertiary HHT referral center. Patients with a definite diagnosis of HHT and a new indication for antiplatelet or anticoagulant therapy were enrolled. The primary outcome was the incidence of hemorrhagic events, classified according to the International Society on Thrombosis and Haemostasis criteria. Secondary outcomes included worsening of epistaxis assessed by the Epistaxis Severity Score, changes in hemoglobin levels, and transfusion requirements. RESULTS: A total of 33 patients (mean age 65.8 ± 12.9 years; 69.7% male) were included, for a total of 41 AT courses. During a mean follow-up of 21.1 ± 19.2 months, 2 major bleeding events (4.9%) occurred, both during anticoagulant therapy. Three clinically relevant nonmajor bleeds and one minor bleed were recorded. Worsening of epistaxis occurred in 24.4% of treatment courses, but mean Epistaxis Severity Score values did not differ from baseline. Hemoglobin levels and transfusion requirements were not significantly affected. CONCLUSIONS: In this prospective cohort, AT was associated with an acceptable safety profile in selected patients with HHT managed in a multidisciplinary setting. These findings strengthen the currently limited prospective evidence supporting individualized antithrombotic management in HHT, although larger multicenter prospective studies remain warranted.